Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: Findings from the LIBERATE study
Journal of the European Academy of Dermatology and Venereology | Dec 15, 2017
Associations between body mass index and severity of psoriasis
Clinical, Cosmetic and Investigational Dermatology | Dec 05, 2017
Psoriasis and the risk of diabetes: A prospective population-based cohort study
Journal of the American Academy of Dermatology | Nov 22, 2017